These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Wethers DL; Ramirez GM; Koshy M; Steinberg MH; Phillips G; Siegel RS; Eckman JR; Prchal JT Blood; 1994 Sep; 84(6):1775-9. PubMed ID: 8080985 [TBL] [Abstract][Full Text] [Related]
3. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Richard JL; Parer-Richard C; Daures JP; Clouet S; Vannereau D; Bringer J; Rodier M; Jacob C; Comte-Bardonnet M Diabetes Care; 1995 Jan; 18(1):64-9. PubMed ID: 7698050 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Hanft JR; Pollak RA; Barbul A; van Gils C; Kwon PS; Gray SM; Lynch CJ; Semba CP; Breen TJ J Wound Care; 2008 Jan; 17(1):30-2, 34-7. PubMed ID: 18210954 [TBL] [Abstract][Full Text] [Related]
5. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial. Park KH; Han SH; Hong JP; Han SK; Lee DH; Kim BS; Ahn JH; Lee JW Diabetes Res Clin Pract; 2018 Aug; 142():335-344. PubMed ID: 29902542 [TBL] [Abstract][Full Text] [Related]
6. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. Kalani M; Apelqvist J; Blombäck M; Brismar K; Eliasson B; Eriksson JW; Fagrell B; Hamsten A; Torffvit O; Jörneskog G Diabetes Care; 2003 Sep; 26(9):2575-80. PubMed ID: 12941721 [TBL] [Abstract][Full Text] [Related]
7. Topical application of the bee hive protectant propolis is well tolerated and improves human diabetic foot ulcer healing in a prospective feasibility study. Henshaw FR; Bolton T; Nube V; Hood A; Veldhoen D; Pfrunder L; McKew GL; Macleod C; McLennan SV; Twigg SM J Diabetes Complications; 2014; 28(6):850-7. PubMed ID: 25239451 [TBL] [Abstract][Full Text] [Related]
8. Accelerated healing and reduced need for grafting in pediatric patients with burns treated with arginine-glycine-aspartic acid peptide matrix. RGD Study Group. Hansbrough JF; Herndon DN; Heimbach DM; Solem LD; Gamelli RL; Tompkins RG J Burn Care Rehabil; 1995; 16(4):377-87. PubMed ID: 8582916 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Wieman TJ; Smiell JM; Su Y Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the combination of isosorbide dinitrate spray and chitosan gel for the treatment of diabetic foot ulcers: A double-blind, randomized, clinical trial. Totsuka Sutto SE; Rodríguez Roldan YI; Cardona Muñoz EG; Garcia Cobian TA; Pascoe Gonzalez S; Martínez Rizo A; Mendez Del Villar M; García Benavides L Diab Vasc Dis Res; 2018 Jul; 15(4):348-351. PubMed ID: 29682995 [TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Niezgoda JA; Van Gils CC; Frykberg RG; Hodde JP Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317 [TBL] [Abstract][Full Text] [Related]